Moyamoya disease
ICD-10 I67.5 is a billable code used to indicate a diagnosis of moyamoya disease.
Moyamoya disease is a progressive cerebrovascular disorder characterized by stenosis or occlusion of the internal carotid arteries and their proximal branches, leading to the formation of a network of collateral vessels that resemble a 'puff of smoke' on angiography, hence the name 'Moyamoya' which means 'puff of smoke' in Japanese. Clinically, patients may present with transient ischemic attacks (TIAs), strokes, or neurological deficits due to reduced cerebral blood flow. The disease predominantly affects children and young adults, but it can occur at any age. The anatomy involved includes the internal carotid arteries and the anterior and middle cerebral arteries. Disease progression can lead to recurrent strokes and significant morbidity. Diagnosis is typically confirmed through imaging studies such as magnetic resonance angiography (MRA) or digital subtraction angiography (DSA), which visualize the characteristic vascular changes. Early diagnosis and intervention are crucial to prevent severe neurological outcomes.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
I67.5 specifically covers Moyamoya disease, which includes the characteristic occlusion of the internal carotid arteries and the development of collateral circulation. It does not cover other forms of cerebrovascular disease.
I67.5 should be used when a patient is diagnosed with Moyamoya disease, characterized by specific angiographic findings. It should not be used for general strokes or transient ischemic attacks without the distinct features of Moyamoya.
Documentation should include clinical evaluations, imaging studies (MRA or DSA), and any relevant history of ischemic events. Detailed notes on symptoms and neurological assessments are also essential.
